---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-034601"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2026-07-24T21:00:37+00:00"
generated_at: "2026-07-24T21:02:31.735158+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BTIG terminates $50M at-the-market sales agreement with Matinas BioPharma

## Summary
- BTIG terminated the ATM sales agreement effective July 23, 2026, under Section 12(a).
- The agreement allowed Matinas to sell up to $50M of common stock through BTIG.
- No termination penalties or expenses incurred by the company.
- Matinas loses access to this equity financing facility.

## SEC filing metadata
- accession: 0001493152-26-034601
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2026-07-24T21:00:37+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315226034601/0001493152-26-034601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315226034601/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-034601
- JSON: https://secwatch.observer/filing/0001493152-26-034601.json
- Plain text: https://secwatch.observer/filing/0001493152-26-034601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.